Prostate Cancer Press Releases
Breaking News
-
Firminite Fast-Acting Male Enhancer Announces Release of Trial Packs for New Customers
ALLEN, TX—(EIN PRESSWIRE—April 2nd, 2011)—West Coast Nutritionals, LLP - the makers of the male enhancement pill, Firminite (online at www.firminite.com/product.php) - has announced the launch of discounted trial packs of the male enhancer...
-
Firminite Male Enhancer Pill Pounding Competition with Proprietary Fast-Acting Absorption Technology
ALLEN, TX--(EIN PRESSWIRE--April 2nd, 2011)--West Coast Nutritionals, LLP - the makers of the natural male enhancement pill, Firminite (online at www.Firminite.com), is enjoying strong second quarter gains thanks to the proprietary fast-acting...
-
Food Manufacturers Get Proactive against BPA
Nov. 3, 2010 /EIN Presswire/ -- Health officials from many nations continued to reach a consensus in Toronto about the safety of the chemical Bisphenol A (BPA) in food packaging, but the food industry already seems to have come up with its verdict:...
-
WholesaleInsurance.net Publishes Term Life Insurance Guide To Clarify Customer's Insurance Options
Leading life insurance provider, WholesaleInsurance.net, recently published a term life insurance guide to help customers understand life insurance options. The guide provides a basic outline of the many different types of policies available. ROSEVILLE,...
-
Helpful Holistic Skin Care Tip: For A Glowing Complexion, Rev Up Your Digestion
Nikkel Holistic Skincare founder Dana McCants shares tips on how to improve skin through better digestion. "While topical beauty products can be helpful, beautiful and blemish-free, skin is a reflection of a good digestive system," says Dana...
Press Releases
Prostate Cancer
-
FDA News & Notes - Week of February 6, 2012
FDA News & Notes - Week of February 6, 2012 PR Newswire SILVER SPRING, Md. , Feb. 6, 2012 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this...
-
Genomic Health Announces Formation of New Genetics Subsidiary
Genomic Health Announces Formation of New Genetics Subsidiary New Venture to Focus on Integrating Clinically Relevant Genetic Information from the Human Genome into Routine Medical Practice Randy Scott to Lead Subsidiary, Kim Popovits to...
-
Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook - Full-Year Product Revenue Increased 17 Percent Compared with 2010 - - Delivered Net Income of $7.8 Million - - Launched Oncotype DX® DCIS Score...
-
FDA News & Notes -- Week of February 6, 2012
FDA News & Notes -- Week of February 6, 2012 PR Newswire SILVER SPRING, Md. , Feb. 6, 2012 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information...
-
CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015
CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 PR Newswire ALBANY, New York ,...
-
CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015
CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 PR Newswire ALBANY, New York ,...
-
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others PR Newswire NEW YORK , Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market...
-
Triple Analysis: Breast Cancer, Prostate Cancer and Angiogenesis
Triple Analysis: Breast Cancer, Prostate Cancer and Angiogenesis PR Newswire NEW YORK , Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Triple Analysis:...
-
Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary Cancers Symposium
Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary Cancers Symposium New Data Support Prostate Cancer Test Development Program PR Newswire REDWOOD CITY,...
-
Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting PR Newswire QUÉBEC CITY, Feb. 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)...
-
Team Led By Scripps Research Scientists Demonstrates Effective New 'Biopsy in a Blood Test' to Detect Cancer
Team Led By Scripps Research Scientists Demonstrates Effective New 'Biopsy in a Blood Test' to Detect Cancer PR Newswire Series of Five Studies Highlights Potential of Technology to Boost Patient Care, Research LA...
-
Molecular Insight Pharmaceuticals, Inc. Presents Human Data Demonstrating Detection of Metastatic Prostate Cancer
Molecular Insight Pharmaceuticals, Inc. (MIP) will present first human data on the molecular imaging of metastatic prostate cancer in bone and soft tissue with their new 99m Tc-radiolabeled compounds. The data will be highlighted at a scientific...
-
Bayer Initiates Expanded Access Program for Investigational Compound Radium-223 Chloride
Bayer Initiates Expanded Access Program for Investigational Compound Radium-223 Chloride PR Newswire WAYNE, N.J. , Feb. 2, 2012 /PRNewswire/ -- Bayer HealthCare, LLC today announced that the U.S. Food and Drug Administration...
-
Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer
Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer Data Support Ongoing Phase 2 Study in Metastatic Bladder Cancer PR Newswire BOTHELL, Wash. and...
-
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer OncoGenex Announces Plans to Initiate a Phase 2 Study of OGX-427...
Follow us
What people say
Our Partners
© 2005-2012